BC Platforms has acquired real-world data (RWD) firm Medexprim, citing a desire to provide biopharma partners with access to clinical and imaging data assets across Europe.
Medexprim structures real world clinical and imaging data with a focus on oncology, neurology, cardiology, and rare diseases. The firm has links with hospitals and pharmaceutical companies, with a footprint in France, Germany, and Spain. It employs 35 people in Toulouse and Paris in France.
BC Platforms CEO Tero Silvola told us, in addition to adding technical capabilities and geographic reach, the Medexprim acquisition is about synergy.
“We gain several synergies: Revenue synergies as we are talking to the same clients. Cost synergies in data sources and data network development. Talent related synergies in building a world class team in RWD understanding. Data coverage synergies as we have complementing ways to collect and build data access and also slightly different geographies.”
This acquisition follows BC Platforms' buyout of 4Pharma, a contract research organization which provides medical research services to pharmaceutical, biotechnology, and medical device companies.
Buying Medexprim is a complementary deal according to Silvola.
“Medepxrim is a technology and data enterprise. 4Pharma was a data analytics and intelligence enterprise. There is no overlap, but again plenty of synergies. 4Pharma complements Medepxrim operations, just like it does to BC Platforms.”
Both deals are part of a wider plan to expand BC’s customer base according to Silvola, citing firms in the clinical services space as an example.
He told us “We have been scouting different ways to work with CROs. It is an additional growth opportunity and we do see an opportunity to provide new value for them. At the moment the majority of the sales comes from the Life Science companies and Healthcare.”
The acquisition is part of a wider growth plan according to Laurent Samama, managing partner at BC Platform investor Jolt Capital, who said "We see an opportune moment for accelerated growth, solidifying our position as the foremost global precision medicine platform company.”
DepositPhotos/denisismagilov